BridgeBio Pharma’s Attruby generated net product revenue of $222.4 million in Q2 2026, more than tripling the $71.5 million recorded in the same period a year ago.
Total revenues climbed 120% to $243.7 million, underscoring the drug’s rapid commercial momentum since its launch in the transthyretin amyloid cardiomyopathy market.
Attruby posted 23% sequential quarterly growth, outpacing the broader ATTR-CM market’s 19% growth rate during the same period.
Management attributed much of that outperformance to gains in the treatment-naive, first-line patient segment, where Attruby is increasingly becoming the physician’s drug of choice.
BridgeBio reaffirmed that Attruby is on track to achieve blockbuster status in 2026, with the company projecting operating profit breakeven by 2027.
The blockbuster target refers to worldwide sales of acoramidis, which includes Beyonttra sales recorded by partners outside the United States, rather than U.S. Attruby net product revenue alone.
BridgeBio’s leadership is sharpening its commercial strategy around what it calls the ‘stabilizer-first’ market dynamic, believing its near-complete stabilizer holds a biological advantage over partial stabilizers in this indication.
The failure of the CARDIO-TTRansform combination therapy trial was viewed by management as reinforcing stabilizers as the first-line standard of care, further strengthening Attruby’s competitive positioning in the market.
Management is characterising the current commercial period as ‘Launch 2.0’ for Attruby, driven by a wave of new clinical data highlighting the drug’s kidney-protective effects and superior real-world outcomes.
New data unveiled by the company showed a 37% reduction in cardiovascular events versus tafamidis, a finding that is expected to play a central role in physician conversations and market share growth going forward.
The FDA accepted three marketing applications from BridgeBio with priority review designations, covering BBP-418 for limb-girdle muscular dystrophy, encaleret for ADH1, and infigratinib for achondroplasia.
PDUFA dates for those three candidates are set for November 27, 2026, May 8, 2027, and mid-2027 respectively, representing a significant near-term pipeline catalyst schedule for the company.
BridgeBio closed a $1 billion preferred equity financing on July 1, 2026, bringing its total cash position to approximately $1.7 billion to fund three upcoming product launches and ongoing operations.
The company’s expanding financial runway positions it to execute on what management describes as its fourth, fifth, and sixth medicines entering the commercial stage in the near term.